Safety and Immunogenicity of NVX-CoV2705
Public ClinicalTrials.gov record NCT07079670. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to 64 who have existing health conditions that put them at high risk for severe COVID-19. All participants must have received a previous COVID-19 vaccine at least 90 days before joining this study. Study researchers will be closely monitoring participants for their immune response for 28 days and collecting safety data for 180 days after vaccination.
Study identification
- NCT ID
- NCT07079670
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 676 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 8, 2025
- Primary completion
- Jan 11, 2026
- Completion
- May 10, 2026
- Last update posted
- Jun 4, 2026
2025 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number US404 | Phoenix | Arizona | 85044 | — |
| Investigational Site Number US395 | Melrose Park | Illinois | 60160 | — |
| Investigational Site Number US406 | Lenexa | Kansas | 66219 | — |
| Investigational Site Number US294 | Lafayette | Louisiana | 70508 | — |
| Investigational Site Number US407 | Southfield | Michigan | 48076-5412 | — |
| Investigational Site Number US326 | Omaha | Nebraska | 68134 | — |
| Investigational Site Number US381 | Cincinnati | Ohio | 45246-2316 | — |
| Investigational Site Number US047 | Austin | Texas | 78705-3298 | — |
| Investigational Site Number US073 | Tomball | Texas | 77375 | — |
| Investigational Site Number US391 | Pleasant View | Utah | 84404-4791 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07079670, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07079670 live on ClinicalTrials.gov.